A novel therapeutic strategy for #NMIBC: OncoTherad® immunotherapy associated with platelet-rich plasma. #BeyondTheAbstract with Bianca Ribeiro de Souza, PhD @UBC on UroToday > bit.ly/43pQ7RD

Phase I trial of intravesical BCG combined with intravenous pembrolizumab in recurrent or persistent high-grade #NMIBC after previous BCG treatment. #BeyondTheAbstract on UroToday > bit.ly/3UTiGEI @wjurol

An analysis in #NMIBC patients - a comparative study of white light and blue light cystoscopy in an equal access setting. @SWilliams_MD @UTMBUrology joins @zklaassen_md @GACancerCenter in this discussion on UroToday > bit.ly/47uDHYR @PhotocureASA @Cysview

Cretostimogene grenadenorepvec in BCG-unresponsive #NMIBC: a discussion on the #BOND-003 and #CORE1 trials. @tbivala1 @Penn joins @UroCancerMD @VUMCurology to discuss treatments in NMIBC, CG0070 & its efficacy in managing BCG-unresponsive CIS > bit.ly/4a6uS9m @cgoncology

Exciting developments in #BladderCancer treatment! Check out this groundbreaking study on OncoTherad® (MRB-CFI-1) Nanoimmunotherapy for BCG-Unresponsive #NMIBC. Promising results offer hope for improved outcomes and reduced need for radical surgery > bit.ly/3xNNKMO

Combining pembrolizumab and BCG immunotherapies: The #KEYNOTE676 trial in high-risk #NMIBC. Neal Shore, MD, FACS @CURCMB joins @UroCancerMD @VUMCurology in this discussion on the potential synergy between these two immunotherapeutic agents > bit.ly/3QhcwLo

Genetic overlap discovered between cancerous and non-cancerous bladder tissue in small study. @UrogerliMD @MoffittNews joins @UroCancerMD @VUMCurology to discuss genetic profiles in #NMIBC and adjacent benign bladder tissue > bit.ly/3UvRiMC

✨When Dr. Ashish Kamat speaks on #bladdercancer, you listen. He has authored a book on #NMIBC #Anktiva N-803 $IBRX

Ashish M. Kamat, MD, MBBS @UroDocAsh

a week ago

✨When Dr. Ashish Kamat speaks on #bladdercancer, you listen. He has authored a book on #NMIBC #Anktiva N-803 $IBRX https://t.co/XoVY8ziWJ7

1 10 41 7K 4

ICYMI: ImmunityBio management recently provided an update on registration plans for #NSCLC, status of #ANKTIVA launch readiness for #NMIBC, and ANKTIVA as the backbone of company’s clinical trial pipeline for multiple tumor types. Learn more: immunitybio.com/investor-live-…

$CGON, pre-Rev biotech listed this Jan, gets the $IBRX lift ... CG0070 is potentially the most efficacious #NMIBC On May 3 AMC, the co will provide updates after presentation at #AUA24. On May 30, update on Phase-2 trials (CORE-001) at #ASCO24 #cancer #AUA #Oncology

trendwhizo @trendwhizo

a week ago

$CGON, pre-Rev biotech listed this Jan, gets the $IBRX lift ... CG0070 is potentially the most efficacious #NMIBC On May 3 AMC, the co will provide updates after presentation at #AUA24. On May 30, update on Phase-2 trials (CORE-001) at #ASCO24 #cancer #AUA #Oncology https://t.co/P7EmioA0xN

1 2 5 4K 0

Download Image

ImmunityBio's first-in-class IL-15 receptor agonist #ANKTIVA® gets FDA nod for BCG-resistant bladder cancer. Promising a paradigm shift in #NMIBC care. Launching mid-May 2024. #BladderCancer #Immunotherapy $IBRX immunitybio.com/immunitybio-an…

Join Dr. Jeremy Teoh for an enlightening session at #JUA2024 where he explores how understanding the recurrence mechanism of #NMIBC could lead to the optimization of oncological outcomes. Don't miss out on this informative discussion! @jteoh_hk 🔎Find out more about JUA2024…

Wonderful to have @JoCresswell4 as the @GuysUrology visiting professor @GSTTnhs Lecturing on #nmibc and widening participation @BAUSurology

keyboard_arrow_left Previous keyboard_arrow_right Next

The role of gene therapy in enhancing #BladderCancer patient outcomes. @MarkTysonMD @MayoClinic joins Neal Shore, MD, FACS @CURCMB to discuss advances in #NMIBC treatments, particularly for BCG-unresponsive patients. #WatchNow > bit.ly/42Sdram @ferring

🚨Just published in @UrolOncol our latest paper on the role of urinary cytology predicting risk category in #NMIBC by @cgdelcanizo 📖Read it here: t.ly/J3FKQ @so_uro

keyboard_arrow_left Previous keyboard_arrow_right Next

Sharing this poll from @UroDocAsh On #NMIBC Questions asked in the right way to get some great insights related to the variety of treatments used on #BladderCancer

Ashish M. Kamat, MD, MBBS @UroDocAsh

a week ago

Sharing this poll from @UroDocAsh On #NMIBC Questions asked in the right way to get some great insights related to the variety of treatments used on #BladderCancer

1 7 9 4K 0

@US_FDA recently approved nogapendekin alfa inbakicept with Bacillus Calmette-Guérin (BCG) to treat adult patients with BCG-unresponsive non–muscle-invasive bladder cancer ( #NMIBC ) with carcinoma in situ. Learn more here: ow.ly/sZLC50RmAQt

@RKSayyid and @zklaassen_md explore recommendations from the @sitcancer and the @IBCG_BladderCA for designing clinical trials in high-risk #NMIBC. The consensus statement aims to guide investigators in late-phase clinical trial design > bit.ly/42P2Hts @UroDocAsh